BOULDER, Colo.--(BUSINESS WIRE)-- Array BioPharma Inc. (NASDAQ: ARRY) today announced data will be presented on two drug candidates, ARRY-520, a KSP inhibitor, and ARRY-614, a dual p38/Tie2 inhibitor, at the 2011 Annual Meeting of the American Society of Hematology in San Diego, California.
The abstracts can be accessed through the American Society of Hematology website, www.hematology.org/Meetings/Annual-Meeting. The abstract titles are provided below; however, please note that according to ASH press policies, all data are embargoed until the time of the beginning of the presentation. After the presentations, the posters and presentation slides will be available as PDFs on Array's website at www.arraybiopharma.com.
|
Poster: |
ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study (Publication #1860) |
||
|
Date: |
Saturday, December 10, 2011 | ||
|
Time: |
5:30–7:30 p.m. PST | ||
|
Location: |
San Diego Convention Center, Hall GH | ||
|
Oral Presentation: |
Phase 1 Dose-Escalation/Expansion Study of the p38/Tie2 Inhibitor ARRY-614 in Patients with IPSS Low/Int-1 Risk Myelodysplastic Syndromes (Abstract #118) |
||
|
Presenter: |
Rami S. Komrokji, M.D., Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute | ||
|
Date: |
Sunday, December 11, 2011 | ||
|
Time: |
5:15 p.m. PST | ||
|
Location: |
San Diego Convention Center, Room 6CF | ||
|
Poster: |
The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma (MM) (Publication #2935) |
||
|
Date: |
Sunday, December 11, 2011 | ||
|
Time: |
6–8 p.m. PST | ||
|
Location: |
San Diego Convention Center, Hall GH | ||
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Our proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target proteins and are aimed at significant unmet medical needs. For more information on Array, please go to www.arraybiopharma.com.
CONTACT:
Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
[email protected]
KEYWORDS: United States North America California Colorado
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical Research Science
MEDIA:
| Logo |